IN- VITRO EVALUATION OF NANOCURCUMIN AGAINST MULTI-DRUG RESISTANT BACTERIA

Ibrahim, Noha Mohammed Safwat; B. Hassan, Ehsan A.; Elgendy, Sherein G.; Hassan, Hebatallah M.; Hassan, Abeer S.; El-Gindy, Niveen G.

doi:10.21608/bfsa.2023.301135

IN- VITRO EVALUATION OF NANOCURCUMIN AGAINST MULTI-DRUG RESISTANT BACTERIA

Document Type : Original Article

Authors

¹ Department of Microbiology and Immunology, Faculty of Pharmacy, Assuit University

² Department of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Egypt

³ Department of Pharmaceutics, Faculty of Pharmacy, South Valley University, Egypt

⁴ Department of Industrial Pharmacy, Faculty of Pharmacy, Assiut University, Egypt

10.21608/bfsa.2023.301135

Abstract

A natural substance called curcumin, derived from the Curcuma longa plant, is frequently used to fight both gram-positive and gram-negative bacteria.It is poorly soluble in water so it has low bioavailability. The aim of this work was to develop effective nanocurcumin formulation to enhance its water solubility and antibacterial activity against four types of multidrug resistant strains. Nanocurcumin was formulated with different combined stabilizers employing antisolvent nanoprecipitation approach and then evaluated in terms of particle size, zetapotential and transmission electron microscopy. The optimized nanocurcumin formulation containing and Polyvinylpyrrolidone K30 (PVP) and Polyethylene glycol 6000(PEG6000) was selected for the In-vitro antibacterial studies against Staphylococcus aureus ATCC® 43300™*, Escherichia coli ATCC® 8739™*, Pseudomonas aeruginosa ATCC® 27853™* and Klebsiella pneumoniae ATCC® 33495™* compared with free curcumin. The prepared nanocurcumin formulation showed mean particle size of 272.15 ± 34.5 nm and polydispersity index (PDI) of 0.423 and high drug content percent ((95.5 ± 1.5 %). The in-vitro antibacterial studies exhibited that the minimum inhibitory concentration (MICs) of free curcumin are 5011, 2511, 10000 and 10000 µg/ml against Staphylococcus aureus ATCC® 43300™*, Escherichia coli ATCC® 8739™*, Pseudomonas aeruginosa ATCC® 27853™* and Klebsiella pneumoniae ATCC® 33495™*, respectively while the MICs of nanocurcumin are 128.8, 549.5, 67.60 and 312.2 µg/ml against Staphylococcus aureus ATCC® 43300™*, Escherichia coli ATCC® 8739™*, Pseudomonas aeruginosa ATCC® 27853™* and Klebsiella pneumoniae ATCC® 33495™*, respectively. It showed highly reduced growth rate of tested strains. Curcumin in nanosized form has remarkable antibacterial activity against Staphylococcus aureus ATCC® 43300™*, Escherichia coli ATCC® 8739™*, Pseudomonas aeruginosa ATCC® 27853™* and Klebsiella pneumoniae ATCC® (MDRO) compared with free curcumin.

Keywords